Vanda Pharmaceuticals Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$94.8M
Doctors Paid
29,128
Transactions
158,604
2024 Total
$16.9M
Payment Breakdown by Category
Research$86.7M (91.4%)
Food & Beverage$3.3M (3.5%)
Travel$604,482 (0.6%)
Consulting$76,669 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $86.7M | 6,417 | 91.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.0M | 875 | 4.2% |
| Food and Beverage | $3.3M | 147,539 | 3.5% |
| Travel and Lodging | $604,482 | 1,686 | 0.6% |
| Charitable Contribution | $92,500 | 7 | 0.1% |
| Consulting Fee | $76,669 | 15 | 0.1% |
| Grant | $60,000 | 1 | 0.1% |
| Education | $15,416 | 2,064 | 0.0% |
Payments by Type
Research
$86.7M
6,417 transactions
General
$8.2M
152,187 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER | $22.2M | 2 | 255 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS | $13.5M | 2 | 1,349 |
| EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | $8.8M | 2 | 852 |
| Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis | $5.0M | 0 | 1,000 |
| AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | $4.6M | 1 | 389 |
| ODYSSEY: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN TREATING SEVERE OR CRITICAL COVID-19 INFECTION | $3.2M | 0 | 76 |
| Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis | $2.5M | 1 | 440 |
| An Observational Study to Investigate the Effects of Rapid Transmeridian Travel | $1.9M | 0 | 41 |
| Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia | $1.8M | 1 | 26 |
| A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | $1.8M | 1 | 75 |
| EVALUATING THE EFFECTS OF VQW-765 VS. PLACEBO IN PERFORMANCE ANXIETY | $1.8M | 1 | 152 |
| A RANDOMIZED STUDY INVESTIGATING THE EFFICACY OF TRADIPITANT IN TREATING MOTION SICKNESS | $1.7M | 1 | 121 |
| Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis | $1.1M | 2 | 179 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis | $967,355 | 2 | 97 |
| EVALUATING THE EFFECTS OF TRADIPITANT VS. PLACEBO IN ATOPIC DERMATITIS | $814,400 | 1 | 315 |
| SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS | $772,162 | 0 | 73 |
| EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) | $757,327 | 1 | 106 |
| SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS | $690,045 | 0 | 240 |
| Tolerability Study of VTR-297 in Subjects With Relapsed or Refractory Hematologic Malignancies | $687,082 | 0 | 25 |
| An Open-label, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long Acting Injectable in Subjects with Schizophrenia | $685,829 | 1 | 20 |
| COLUMBIA: WHOLE GENOME SEQUENCING ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS | $654,334 | 0 | 2 |
| STUDY TO EVALUATE THE EFFECT OF FOOD ON VHX-896 IN HEALTHY VOLUNTEERS | $639,067 | 0 | 12 |
| AN OPEN LABEL, TWO-PERIOD, TWO-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF THE CAPSULE FORMULATION OF TRADIPITANT IN HEALTHY PARTICIPANTS IN A FED AND FASTED STATE. | $600,804 | 0 | 10 |
| AN OPEN-LABEL, TWO-PERIOD, RANDOMIZED, SINGLE ORAL DOSE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF 20 MG TASIMELTEON CAPSULE FORMULATION RELATIVE TO 5 ML TASIMELTEON LIQUID SUSPENSION FORMULATION IN HEALTHY VOLUNTEERS | $596,202 | 0 | 4 |
| BIOEQUIVALENCE STUDY BETWEEN VHX-896 TABLETS AND ILOPERIDONE TABLETS IN HEALTHY VOLUNTEERS | $577,536 | 0 | 11 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness During Vehicle Travel | $528,006 | 0 | 5 |
| A STUDY TO EVALUATEILOPERIDONELONG-ACTING INJECTION (LAI) FOR THE TREATMENT OF SCHIZOPHRENIA | $484,168 | 1 | 35 |
| Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS | $480,510 | 0 | 43 |
| TOLERABILITY STUDY OF VTR-297 IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | $476,976 | 0 | 56 |
| PHARMACOKINETIC STUDY OF VHX-896 AND ILOPERIDONE TABLETS UNDER STEADY-STATE CONDITIONS | $389,491 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors — Page 7
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Irina Herrera, Pmhnp, PMHNP | Psychiatric/Mental Health | Palm Harbor, FL | $1,873 | $0 |
| Alejandro Alva, M.d, M.D | Psychiatry | Costa Mesa, CA | $1,850 | $0 |
| Unknown Provider | — | — | $1,831 | $0 |
| Unknown Provider | — | — | $1,819 | $0 |
| Steven Corder, Md, MD | Psychiatry | Wheeling, WV | $1,798 | $0 |
| Jennifer Sebastian, Pa-C, PA-C | Medical | Costa Mesa, CA | $1,794 | $0 |
| Bhadreshkumar Parikh, M.d, M.D | Psychiatry | Tamarac, FL | $1,781 | $0 |
| Said Jacob, M.d, M.D | Psychiatry | Glendora, CA | $1,775 | $0 |
| David Linden, M.d, M.D | Psychiatry | Las Vegas, NV | $1,774 | $0 |
| Adonis Al-Botros, Md, MD | Psychiatry | Oklahoma City, OK | $1,773 | $0 |
| Dr. Womesh Sahadeo, M.d, M.D | Psychiatry | West Palm Beach, FL | $1,761 | $0 |
| Unknown Provider | — | — | $1,757 | $0 |
| Ignacio Valdes, M.d, M.D | Psychiatry | Houston, TX | $1,752 | $0 |
| Yvette Elpidio, Pmhnp-Bc, PMHNP-BC | Psychiatric/Mental Health | Orange, CA | $1,745 | $0 |
| Dr. Fernando Taveras, Md, MD | Psychiatry | New York, NY | $1,739 | $0 |
| Thy Lam | Registered Nurse | Vista, CA | $1,722 | $0 |
| Dr. Shahid Insaf, Md, MD | Psychiatry | Branson, MO | $1,713 | $0 |
| Dr. Erum Shahab, M.d, M.D | Psychiatry | Ellington, CT | $1,700 | $0 |
| Shahzad Hashmi, M.d.,, M.D., | Psychiatry | Gainesville, GA | $1,697 | $0 |
| Dr. Giovanny Nunez, Md, MD | Psychiatry | New York, NY | $1,688 | $0 |
| Dr. Gregg Friedman, Md, MD | Psychiatry | Hallandale Beach, FL | $1,684 | $0 |
| Mark Cannon, M.d, M.D | Psychiatry | Kansas City, MO | $1,661 | $0 |
| Dr. Ramakrishna Gollamudi, Md, MD | Psychiatry | Dayton, OH | $1,660 | $0 |
| Armand Schachter, Md, MD | Psychiatry | Birmingham, AL | $1,651 | $0 |
| Mr. Mark Clarke, Npp32626, NPP32626 | Family | Smithfield, RI | $1,642 | $0 |
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. has made $94.8M in payments to 29,128 healthcare providers, recorded across 158,604 transactions in the CMS Open Payments database. In 2024, the company paid $16.9M. The top product by payment volume is FANAPT ($28.3M).
Payments were distributed across 234 medical specialties. The top specialty by payment amount is Psychiatry ($3.8M to 6,157 doctors).
Payment categories include: Food & Beverage ($3.3M), Consulting ($76,669), Research ($86.7M), Travel & Lodging ($604,482).
Vanda Pharmaceuticals Inc. is associated with 5 products in the CMS Open Payments database, including FANAPT, Hetlioz, and HETLIOZ.